View the Patent Register
With effect from 1 March 2012, the Intellectual Property Office took over responsibility for the registration and administration of patents from the Greffe and the Royal Court.
The table below details the patents that have been registered in the Bailiwick of Guernsey and their current status.
Register Search -
If you wish to search for a specific Patent or Proprietor please press 'Ctrl F' in order to search this web page.
More detailed information regarding the original application and any subsequent administration can be found by requesting a Statement of the Register. This can be obtained by emailing enquiries@guernseyregistry.com, attaching a Request for copy documents [471kb] form and details of payment (£25 - uncertified copy, £50 - certified copy).
Alternatively, further information regarding the overseas reference is available from the register of the United Kingdom Intellectual Property Office.
Should you require any further information please contact the Registry. Our office opening hours and contact details can be found through the 'contact' section of our website here: http://www.guernseyregistry.com/contact
Last updated: 30/10/2023
Guernsey Reference | Patent Title | Proprietor Name | Overseas Jurisdiction | Overseas Reference | Patent Status |
---|---|---|---|---|---|
GG-GP698 | NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG | The European Patent Office | EP2758388 | Current |
GG-GP697 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED | The European Patent Office | EP3551622 | Current |
GG-GP696 | Pharmaceutical compositions comprising AZD9291 | ASTRAZENECA AB | The European Patent Office | EP3089741 | Current |
GG-GP695 | Compounds and conjugates thereof | MedImmune Limited | The European Patent Office | EP3946464 | Current |
GG-GP694 | Modulators of cystic fibrosis transmembrane conductance regulator | Vertex Pharmaceuticals Incorporated | The European Patent Office | EP3203840 | Current |
GG-GP693 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. | The European Patent Office | EP3500564 | Current |
GG-GP692 | Certain triazolopyrazines, compositions thereof and methods of use therefor | Hutchison Medipharma Limited | The European Patent Office | EP3795573 | Current |
GG-GP691 | Compositions and methods for modulating ttr expression | IONIS PHARMACEUTICALS, INC. | The European Patent Office | EP3524680 | Current |
GG-GP690 | Anti-her3 antibody-drug conjugate | AIICHI SANKYO COMPANY, LIMITED & DAIICHI SANKYO EUROPE GMBH | The European Patent Office | EP3129063 | Current |
GG-GP689 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB & EOLAS THERAPEUTICS INC. | The European Patent Office | EP3414241 | Current |
GG-GP688 | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same | MEDIMMUNE LIMITED | The European Patent Office | EP3277717 | Current |
GG-GP687 | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof | ASTRAZENECA AB | The European Patent Office | EP3411038 | Current |
GG-GP686 | Anti-lag3 antibodies and antigen-binding fragments | Merck Sharp & Dohme LLC | The European Patent Office | EP3182999 | Current |
GG-GP685 | In silico design of mammalian promoters with user-defined functionality | MEDIMMUNE LIMITED | The European Patent Office | EP3612628 | Current |
GG-GP684 | N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors | Redx Pharma PLC | The European Patent Office | EP3204381 | Current |
GG-GP683 | Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors | Hutchison Medipharma Limited | The European Patent Office | EP3511330 | Current |
GG-GP682 | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) | Incyte Corporation | The European Patent Office | EP3746429 | Current |
GG-GP681 | Glucagon and glp-1 co-agonists for the treatment of obesity | MEDIMMUNE LIMITED | The European Patent Office | EP3495380 | Current |
GG-GP680 | Embedded multiple-part sensor within a plunger rod to capture and transmit injection information | MedImmune, LLC | The European Patent Office | EP3554587 | Current |
GG-GP679 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | AstraZeneca AB | The European Patent Office | EP3686193 | Current |
GG-GP678 | Antibodies against cd38 for treatment of multiple myeloma | GENMAB A/S | The European Patent Office | EP2567976 | Current |
GG-GP677 | Systems and methods for generating and maintaining immutable digital meeting records within distributed network nodes. | NORTHERN TRUST CORPORATION | The European Patent Office | EP3729287 | Current |
GG-GP676 | Sustained release formulations using non-aqueous carriers | Amylin Pharmaceuticals, LLC & AstraZeneca Pharmaceuticals LP | The European Patent Office | EP2341905 | Current |
GG-GP675 | Systems and methods for generating, uploading, and executing codes blocks within distributed network nodes | NORTHERN TRUST CORPORATION | The European Patent Office | EP3896894 | Current |
GG-GP674 | RSV-specific antibodies and functional parts thereof | MedImmune Limited | The European Patent Office | EP3094353 | Current |
GG-GP673 | Polycyclic amide derivatives as CDK9 inhibitors | AstraZeneca AB | The European Patent Office | EP3539961 | Current |
GG-GP672 | Methods for improving asthma symptoms using benralizumab | AstraZeneca AB | The European Patent Office | EP3536339 | Current |
GG-GP671 | Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | Acerta Pharma B.V. | The European Patent Office | EP3613745 | Current |
GG-GP670 | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (ATM) kinase | AstraZeneca AB | The European Patent Office | EP3350180 | Current |
GG-GP669 | Antibodies to alpha-synuclein and uses thereof | MedImmune Limited | The European Patent Office | EP3463435 | Current |
GG-GP668 | Modified RNA encoding VEGF-A polypeptides, formulations, and uses relating thereto | Modernatx, Inc. | The European Patent Office | EP3464338 | Current |
GG-GP667 | Improved alpha-v beta-8 antibodies | MedImmune Limited | The European Patent Office | EP3157561 | Current |
GG-GP666 | Stable, aqueous antibody formulations | AstraZeneca AB | The European Patent Office | EP3060229 | Current |
GG-GP665 | Therapeutic combinations of a BTK inhibitor, a PD-1 inhibitor and/or a PD-L1 inhibitor | Acerta Pharma B.V. | The European Patent Office | EP3179992 | Current |
GG-GP664 | 4'-substituted nucleoside-derivatives as HIV reverse transcriptase inhibitors | Merck Sharp & Dohme Corp. | The European Patent Office | EP3122752 | Current |
GG-GP663 | ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF | Compugen Ltd. | The European Patent Office | EP3347379B1 | Current |
GG-GP662 | Amino-triazolopyridine compounds and their use in treating cancer | AstraZeneca AB | The European Patent Office | EP3558997 | Current |
GG-GP661 | Hand strap for a plastic bag | Papier-Mettler KG | The European Patent Office | EP3770078 | Current |
GG-GP660 | Benzo[b]thiophene compounds as sting agonists | MERCK SHARP & DOHME CORP. | The European Patent Office | EP3523287 | Current |
GG-GP659 | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof | ArQule, Inc. | The European Patent Office | EP3394065 | Current |
GG-GP658 | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | Pfizer Inc. | The European Patent Office | EP3126330 | Current |
GG-GP657 | Substituted dihydroisoquinolinone compounds | Pfizer Inc. | The European Patent Office | EP3157915 | Current |
GG-GP656 | Binding molecules specific for cd73 and uses thereof | MEDIMMUNE LIMITED | The European Patent Office | EP3218406 | Current |
GG-GP655 | Card game interface | Marcus A.Katz | European (UK) | EP3593872B1 | Current |
GG-GP654 | A conditional replicating cytomegalovirus as a vaccine for CMV | Merck Sharp & Dohme Corp. | The European Patent Office | EP3251700 | Current |
GG-GP653 | Neutralization of inhibitory pathways in lymphocytes | Innate Pharma | The European Patent Office | EP3405495 | Current |
GG-GP652 | Therapeutic combinations of a BTK inhibitor and a BCL-2 inhibitor | Acerta Pharma B.V. | The European Patent Office | EP3179991 | Current |
GG-GP651 | Heated inflatable exercise chamber with gas-permeable inner membrane | Hotpod Holdings Ltd. | United States of America | 9708830B2 | Current |
GG-GP650 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BTK-inhibitors | Merck Sharp & Dohme B.V. | The European Patent Office | EP3689878 | Current |
GG-GP649 | A crystal comprising an L-malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-owo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide for use as a medicament | Pharmacia & Upjohn Company LLC | The European Patent Office | EP3168218 | Current |
GG-GP648 | Anti-CD19 antibody formulations | MorphoSys AG | The European Patent Office | EP3475303 | Current |
GG-GP647 | Salts of PI3K inhibitor and processes for their preparation | Incyte Corporation | The European Patent Office | EP3262046 | Current |
GG-GP646 | Bipyrazole salt as JAK inhibitor | Incyte Corporation | The European Patent Office | EP3231801 | Current |
GG-GP645 | Neutralizing anti-influenza A antibodies and uses thereof | Medlmmune, LLC and Hunabs Biomed S.A. | The European Patent Office | EP3052192 | Current |
GG-GP644 | Protease-resistant lipidated GLP-1 analogs | Medlmmune Limited | The European Patent Office | EP3307769 | Current |
GG-GP643 | Plastic bag and hand strap for a plastic bag | Papier-Mettler KG | The European Patent Office | EP3450343 | Current |
GG-GP642 | 4-Imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk-inhibitors | Merck Sharp & Dohme B.V. | The European Patent Office | EP2734522 | Current |
GG-GP641 | Compositions and methods for synthesizing 5'-Capped RNAs | TriLink BioTechnologies, LLC | The European Patent Office | EP3352584 | Current |
GG-GP640 | Methods for increasing forced expiratory volume in asthmatics using benralizumab | AstraZeneca AB | The European Patent Office | EP3520811 | Current |
GG-GP639 | Pharmaceutical compositions for the treatment of CFTR mediated diseases | Vertex Pharmaceuticals Incorporated | The European Patent Office | EP2914248 | Current |
GG-GP638 | Anti-CTLA-4 antibody compositions | Pfizer Products Inc. | The European Patent Office | EP2620450 | Current |
GG-GP637 | ANTIBODIES TO AMYLOID BETA | Medimmune Limited | The European Patent Office | EP2906597 | Current |
GG-GP636 | Anti-trop2 antibody-drug conjugate | Daiichi Sankyo Company & Sapporo Medical University | The European Patent Office | EP3088419 | Current |
GG-GP635 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | Innate Pharma | The European Patent Office | EP3193931 | Current |
GG-GP634 | Use of zirconium silicate for the treatment of hyperkalemia | ZS Pharma, Inc | The European Patent Office | EP2673237 | Current |
GG-GP633 | Immediate release tablet formulations | 1) Astrazeneca AB 2) AstraZeneca UK Limited | The European Patent Office | EP2498759 | Current |
GG-GP632 | Methods of producing immunoconjugates | Medlmmune, LLC | The European Patent Office | EP2934597 | Current |
GG-GP631 | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as EGFR modulators useful for treating cancer | AstraZeneca AB | The European Patent Office | EP3333161 | Current |
GG-GP630 | Sustained release dosage forms for a JAK1 inhibitor | Incyte Corporation | The European Patent Office | EP3030227 | Current |
GG-GP629 | Compositions and methods for inhibiting arginase activity | Calithera Biosciences, Inc. | The European Patent Office | EP3559009 | Current |
GG-GP628 | Purified active polypeptides or immunoconjugates | Medlmmune, LLC | The European Patent Office | EP3434346 | Current |
GG-GP627 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins | Incyte Corporation | The European Patent Office | EP3134403 | Current |
GG-GP626 | Binding molecules specific for ASCT2 and uses thereof | Medlmmune LLC | The European Patent Office | EP3374398 | Current |
GG-GP625 | Applicator for inserting an implant | Merck Sharp & Dohme B.V. | The European Patent Office | EP3417905 | Current |
GG-GP624 | Stable anti-IFNAR1 formulation | AstraZeneca AB | The European Patent Office | EP3337502 | Current |
GG-GP623 | Aryl ethers and uses thereof | Peloton Therapeutics, Inc. | The European Patent Office | EP3417851 | Current |
GG-GP622 | Method for purifying immunoconjugates | MedImmune, LLC | The European Patent Office | EP2613857 | Current |
GG-GP621 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | ViiV Healthcare UK (No. 5) Limited | The European Patent Office | EP3411381 | Current |
GG-GP620 | Aminopyrimidinyl compounds as jak inhibitors | Pfizer Inc | The European Patent Office | EP3183247 B9 | Current |
GG-GP619 | Modified polypeptides for bispecific antibody scaffolds | MedImmune, LLC | The European Patent Office | EP2794905 | Current |
GG-GP618 | Exendin for treating diabetes and reducing body weight
| 1) Amylin Pharmaceuticals, LLC 2) AstraZeneca Pharmaceuticals LP | The European Patent Office | EP2347762 | Current |
GG-GP617 | 4-amino-2-(1H-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-di hydro-5H-pyrrolo[2,3-D]pyrimidine derivatives and the respective (1H-indazol-3-yl) derivatives as cGMP modulators for treating cardiovascular diseases | Merck Sharp & Dohme Corp. | The European Patent Office | EP3394067 | Current |
GG-GP616 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K related disorders | Incyte Holdings Corporation | The European Patent Office | EP2961410 | Current |
GG-GP615 | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain | MedImmune Limited | The European Patent Office | EP3099713 | Current |
GG-GP614 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | Forma Therapeutics, Inc. | The European Patent Office | EP3448859 | Current |
GG-GP613 | Triterpenoids with HIV maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent | ViiV Healthcare UK (No.4) Limited | The European Patent Office | EP3129392 | Current |
GG-GP612 | Macrocyclic mcl1 inhibitors for treating cancer | AstraZeneca AB | The European Patent Office | EP3445767 | Current |
GG-GP611 | (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | AstraZeneca AB | The European Patent Office | EP3097086 | Current |
GG-GP610 | Optically active 2-aryl cyclopropane carboxamide intermediate | AstraZeneca AB | The European Patent Office | EP2644591 | Current |
GG-GP609 | Therapeutic polymeric nanoparticles and methods of making and using same | AstraZeneca AB | The European Patent Office | EP3311845 | Current |
GG-GP608 | Aminopyrimidinyl compounds as jak inhibitors | Pfizer Inc. | The European Patent Office | EP3183247 | Current |
GG-GP607 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | Pfizer Inc. | The European Patent Office | EP3077395 | Current |
GG-GP606 | Compositions, methods & systems for respiratory delivery of two or more active agents | Pearl Therapeutics, Inc | The European Patent Office | EP3111926 | Current |
GG-GP605 | Compositions for respiratory delivery of active agents and associated methods and systems | Pearl Therapeutics, Inc. | The European Patent Office | EP3111927 | Current |
GG-GP604 | CTLA-4 variants | MedImmune Limited | The European Patent Office | EP3207938 | Current |
GG-GP603 | Anti-HER2 antibody-drug conjugate | Daiichi Sankyo Company, Limited | The European Patent Office | EP3101032 | Current |
GG-GP602 | Antibody-drug conjugate | Daiichi Sankyo Company, Limited | The European Patent Office | EP2907824 | Current |
GG-GP601 | Methods and compositions for sustained delivery of drugs | Intratus, Inc. | The European Patent Office | EP2493474 | Current |
GG-GP600 | Delivery of cholesteryl ester to steroidogenic tissues | Alphacore Pharma LLC | The European Patent Office | EP2566505 | Current |
GG-GP599 | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems | Pearl Therapeutics, Inc. | The European Patent Office | EP3106149 | Current |
GG-GP598 | 1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | AstraZeneca AB | The European Patent Office | EP3174881 | Current |
GG-GP597 | Compositions and methods for inhibiting arginase activity | Calithera Biosciences, Inc. | The European Patent Office | EP3368541 | Current |
GG-GP596 | Thioacetate compounds, compositions and methods of use | Ardea Biosciences, Inc. | The European Patent Office | EP2585437 | Current |
GG-GP595 | Thioacetate compounds, compositions and methods of use | Ardea Biosciences, Inc. | The European Patent Office | EP2712861 | Current |
GG-GP594 | Thioacetate compounds, compositions and methods of use | Ardea Biosciences, Inc. | The European Patent Office | EP2975025 | Current |
GG-GP593 |
Antibodies binding beta klotho domain 2 and methods of use thereof
| NGM BIOPHARMACEUTICALS, INC. | The European Patent Office | EP3097122 | Current |
GG-GP592 | Cementitious binders, activators and methods for making concrete | DB Group (Holdings) Limited | The European Patent Office | EP2855394 | Current |
GG-GP591 | Activator composition and method for making concrete | DB Group (Holdings) Limited | United Kingdom | 2525705 | Current |
GG-GP590 | Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo [1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | Acerta Pharma B.V. | The European Patent Office | EP3317281 | Current |
GG-GP589 | Estrogen receptor modulators | AstraZeneca AB | The European Patent Office | EP3494116 | Current |
GG-GP588 | Systems and methods for digital identity management and permission controls within distributed network nodes | Northern Trust Corporation | The European Patent Office | EP3458982 | Current |
GG-GP587 | Anti-B7-H1 antibodies for treating tumors | MedImmune Limited | The European Patent Office | EP3043816 | Current |
GG-GP586 | Antibodies directed to alphaVbeta6 and uses thereof | MedImmune Limited | The European Patent Office | EP2064244 | Current |
GG-GP585 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors | AstraZeneca AB | The European Patent Office | EP3292105 | Current |
GG-GP584 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | AstraZeneca AB | The European Patent Office | EP3227294 | Current |
GG-GP583 | ANTIBODIES THAT SPECIFICALLY BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN AND METHODS OF USE | MedImmune LLC | The European Patent Office | EP2673373 | Current |
GG-GP582 | TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA | 1) PIERIS PHARMACEUTICALS GMBH 2 2) ASTRAZENECA AB | The European Patent Office | EP2580236 | Current |
GG-GP581 | Anti-nkg2a antibodies and uses thereof | Novo Nordisk A/S | The European Patent Office | EP2426150 | Current |
GG-GP580 | Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer | MedImmune Limited | The European Patent Office | EP3142751 | Current |
GG-GP579 | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivative useful in the treatment of cancer | AstraZeneca AB | The European Patent Office | EP3433256 | Current |
GG-GP578 | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus kinases (JAK) | Pfizer Inc. | The European Patent Office | EP2958921 | Current |
GG-GP577 | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) | Medivation Technologies LLC | The European Patent Office | EP2767537 | Current |
GG-GP576 | Treatment regimens using anti-nkg2a antibodies | Innate Pharma | The European Patent Office | EP3193929 | Current |
GG-GP575 | Refrigerator-temperature stable influenza vaccine compositions | MedImmune, LLC | The European Patent Office | EP2769735 | Current |
GG-GP574 | Targeted binding agents against B7-H1 | Medlmmune Limited | The European Patent Office | EP3279215 | Current |
GG-GP573 | Methods for improving asthma symptoms using benralizumab | AstraZeneca AB | The European Patent Office | EP3033103 | Current |
GG-GP572 | Novel fused pyridine compounds as casein kinase inhibitors | Pfizer Inc | The European Patent Office | EP2654750 | Current |
GG-GP571 | Bipyrazole derivatives as JAK inhibitors | Incyte Corporation | The European Patent Office | EP2997023 | Current |
GG-GP570 | Methods for increasing forced expiratory volume in asthmatics using benralizumab | AstraZeneca AB | The European Patent Office | EP 3033104 | Current |
GG-GP569 | Macrocyclic derivatives for the treatment of proliferative diseases | Pfizer Inc. | The European Patent Office | EP 2822953 | Current |
GG-GP568 | Polycyclic amide derivatives as CDK9 inhibitors | AstraZeneca AB | The European Patent Office | EP 3313838 | Current |
GG-GP567 | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use | MedImmune LLC | The European Patent Office | EP 2673373 | Current |
GG-GP566 | 5-phenoxy-3H-pyrimidin-4-one derivatives and their uses as HIV reverse transcriptase inhibitors | Merck Sharp & Dohme Corp | The European Patent Office | EP 2903977 | Current |
GG-GP565 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl | Array BioPharma, Inc. | The European Patent Office | EP 2712358 | Current |
GG-GP564 | Heterocyclylamines as Pl3K inhibitors | Incyte Holdings Corporation | The European Patent Office | EP 2751109 | Current |
GG-GP563 | Tiled pitched roofs | Modugroup Limited | The European Patent Office | EP 2923007 | Current |
GG-GP562 | Substituted tricyclic compounds as FGFR inhibitors | Incyte Holdings Corporation | The European Patent Office | EP2861595 | Current |
GG-GP561 | Benzimidazole derivatives | Pfizer Inc. | The European Patent Office | EP2170860 | Current |
GG-GP560 | Novel selective androgen receptor modulators | Pfizer Inc. | The European Patent Office | EP2925725 | Current |
GG-GP559 | New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc | The European Patent Office | EP3224268 | Current |
GG-GP558 | Methods for reducing exacerbation rates of asthma using benralizumab | AstraZeneca AB | The European Patent Office | EP3033101 | Current |
GG-GP557 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | Pfizer Inc. | The European Patent Office | EP2621493 | Current |
GG-GP556 | Calicheamicin derivative-carrier conjugates | Wyeth Holdings LLC | The European Patent Office | EP1507556 | Current |
GG-GP555 | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta 2 adrenergic receptor agonists and associated methods and systems | Pearl Therapeutics, Inc. | The European Patent Office | EP2435023 | Current |
GG-GP554 | Compositions for respiratory delivery of active agents and associated methods and systems | Pearl Therapeutics, Inc. | The European Patent Office | EP2435024 | Current |
GG-GP553 | Respiratory delivery of active agents | Pearl Therapeutics, Inc. | The European Patent Office | EP2435025 | Current |
GG-GP552 | Modulation of signal transducer and activator of transcription 3 (stat3) expression | Ionis Pharmaceuticals, Inc. | The European Patent Office | EP2697243 | Current |
GG-GP551 | CARD GAME INTERFACE | Marcus A. Katz | The European Patent Office | EP2352563 | Current |
GG-GP550 | Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia | MedImmune Limited | The European Patent Office | EP3041490 | Current |
GG-GP549 | Topical formulation for a JAK inhibitor | Incyte Holdings Corporation | The European Patent Office | EP2574168 | Current |
GG-GP548 | Benzoxazinone amides as mineralocorticoid receptor modulators | AstraZeneca AB | The European Patent Office | EP3160948 | Current |
GG-GP547 | Glucagon/GLP-1 agonists for the treatment of obesity | MedImmune Limited | The European Patent Office | EP2931745 | Current |
GG-GP546 | Lipopeptide compositions and related methods | Cubist Pharmaceuticals LLC | The European Patent Office | EP2504353 | Current |
GG-GP545 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | Incyte Holdings Corporation | The European Patent Office | EP3050882 | Current |
GG-GP544 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | AstraZeneca AB | The European Patent Office | EP3140303 | Current |
GG-GP543 | 1,3,4-thiadiazole compounds and their use in treating cancer | AstraZeneca AB and Cancer Research Technology Limited | The European Patent Office | EP314894 | Current |
GG-GP542 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | Incyte Holdings Corporation | The European Patent Office | EP2545045 | Current |
GG-GP541 | Processes and intermediates for making a JAK inhibitor | Incyte Holdings Corporation | The European Patent Office | EP2753621 | Current |
GG-GP540 | Antiviral therapy | ViiV Healthcare Company | The European Patent Office | EP3127542 | Current |
GG-GP539 | Antiviral therapy | ViiV Healthcare Company | The European Patent Office | EP2932970 | Current |
GG-GP538 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ViiV Healthcare UK (No. 4) Limited | The European Patent Office | EP2801576 | Current |
GG-GP537 | Novel FXR (NR1H4) modulating compounds | Gilead Sciences, Inc. | The European Patent Office | EP2731676 | Current |
GG-GP536 | High purity lipopeptides, lipopeptide micelles and processes for preparing same | Cubist Pharmaceuticals, LLC | The European Patent Office | EP2264047 | Current |
GG-GP535 | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments | Merck Sharp & Dohme Corp. | The European Patent Office | EP2691112 | Current |
GG-GP534 | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds suitable for treatment or prevention of central nervous system disorders | Merck Sharp & Dohme Corp. | The European Patent Office | EP2945632 | Current |
GG-GP533 | Determining a common secret for the secure exchange of information and hierarchical, deterministic cryptographic keys | Nchain Holdings Limited | The European Patent Office | EP3268914 | Current |
GG-GP532 | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus Kinase inhibitors | Incyte Holdings Corporation | The European Patent Office | EP2348023 | Current |
GG-GP531 | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus Kinase inhibitors | Incyte Holdings Corporation | The European Patent Office | EP2343299 | Current |
GG-GP530 | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | Omthera Pharmaceuticals Inc. & Chysalis Pharma AG | The European Patent Office | EP2800563 | Current |
GG-GP529 | N-acylsulfonamide apoptosis promoters | AstraZeneca AB | The European Patent Office | EP2601177 | Current |
GG-GP528 | Novel RIG-I ligands and methods for producing them | Rheinische Friedrich-Wilhelms-Universität Bonn | The European Patent Office | EP2903997 | Current |
GG-GP527 | Method and System for Single Sign on with Dynamic Authentication Levels | HSBC Technology & Services (USA) Inc. | The European Patent Office | EP2304616 | Current |
GG-GP526 | Calicheamicin derivative-carrier conjugates | Wyeth Holdings LLC | The European Patent Office | EP2371392 | Current |
GG-GP525 | 2-(2, 4, 5-substituted-anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer | AstraZeneca AB | The European Patent Office | EP3009431 | Current |
GG-GP524 | Diarylhydantoin compound | The Regents of the University | The European Patent Office | EP1893196 | Current |
GG-GP523 | Chemical compounds | NuCana plc | The European Patent Office | EP2955190 | Current |
GG-GP522 | A conditional replicating cytomegalovirus as a vaccine for CMV | Merck Sharp & Dohme Corp | The European Patent Office | EP2753364 | Current |
GG-GP521 | Biocidal boronophthalide compounds | Anacor Pharmaceuticals, Inc. | The European Patent Office | EP2343304 | Current |
GG-GP520 | Methods for enhanced production of bone morphogenetic proteins | Wyeth LLC | The European Patent Office | EP2310523 | Current |
GG-GP519 | Formulation comprising a gemcitabine-prodrug | NuCana plc | The European Patent Office | EP3119794 | Current |
GG-GP518 | Targeted binding agents against B7-H1 | MedImmune Limited | The European Patent Office | EP25044364 | Current |
GG-GP517 | Therapeutic polymeric nanoparticles and methods of making and using same | AstraZeneca AB | The European Patent Office | EP3046584 | Current |
GG-GP516 | Injection device and method of assembly and activation | Hospira, Inc. | The European Patent Office | EP2021050 | Current |
GG-GP515 | Processes for the convergent synthesis of calicheamicin derivatives | Wyeth LLC | The European Patent Office | EP1987048 | Current |
GG-GP514 | Anti-beta-amyloid antibody and uses thereof | University of Zurich | The European Patent Office | EP2436696 | Current |
GG-GP513 | Modulators of ATP-Binding Cassette transporters | Vertex Pharmaceuticals Incorporated | The European Patent Office | EP2365972 | Current |
GG-GP512 | Key and disc tumbler cylinder lock | Abloy Oy | The European Patent Office | EP2815045 | Current |
GG-GP511 | 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KuDOS Pharmaceuticals Limited | The European Patent Office | EP2057156 | Current |
GG-GP510 | Lipidated immune response modifier compound compositions, formulations, and methods | 3M Innovative Properties Company | European (UK) | EP2606047 | Current |
GG-GP509 | Glucagon/GLP-1 receptor co-agonists | Indiana University Research & Technology Corporation | United Kingdom | EP2723367 | Current |
GG-GP508 | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | Pfizer Inc. | The European Patent Office | EP2445883 | Current |
GG-GP507 | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors | Pfizer Products Inc. | European (UK) | EP1869019 | Current |
GG-GP506 | 1,2,4-triazine-4-amine derivatives | Heptares Therapeutics Limited | European (UK) | EP2531492 | Current |
GG-GP505 | 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl carboxamides as JAK inhibitors | Galapagos N.V | European (UK) | EP2445911 | Current |
GG-GP504 | Pharmaceutical formulation 514 | AstraZeneca UK Limited | European (UK) | EP2346495 | Current |
GG-GP503 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | Warner-Lambert Company LLC | European (UK) | EP1301472 | Current |
GG-GP502 | Antiviral compounds | Gilead Pharmasset LLC | European (UK) | EP2430014 | Current |
GG-GP501 | Inhibitors of hepatitis C virus | Gilead Sciences, Inc. | European (UK) | EP2870160 | Current |
GG-GP500 | Condensed imidazolylimidazoles as antiviralcompounds | Gilead Pharmasset LLC | European (UK) | EP2635588 | Current |
GG-GP499 | Compounds and their use as BACE inhibitors | AstraZeneca AB | European (UK) | EP2655378 | Current |
GG-GP498 | Aminoheteroaryl compounds as protein kinaseinhibitors | Sugen, Inc. | European (UK) | EP2476667 | Current |
GG-GP497 | Heterocyclic modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated | European (UK) | EP2774925 | Current |
GG-GP496 | Apoptosis signal-regulating kinase inhibitor | Gilead Sciences, Inc. | European (UK) | EP2807151 | Current |
GG-GP495 | Automatic injector | Meridian Medical Technologies, Inc. | European (UK) | EP2311510 | Current |
GG-GP494 | A method for fitting a bra | MARKS AND SPENCER PLC | United Kingdom | EP2997841 | Current |
GG-GP493 | Dihydropyrazolopyrimidinone derivative | MSD K.K. | United Kingdom | EP2017278 | Current |
GG-GP492 | Benzodioxinyl substituted indazole derivatives | Astrazeneca AB & Bayer Pharma Aktiengesellschaft | United Kingdom | EP2291369 | Current |
GG-GP491 | Modulators of atp-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | United Kingdom | EP2771345 | Current |
GG-GP490 | Fused bicyclic oxazolidinone cetp inhibitor | MERCK SHARP & DOHME CORP. | United Kingdom | EP2771345 | Current |
GG-GP489 | Bicycloaniline derivative | MSD K.K. | United Kingdom | EP2168966 | Current |
GG-GP488 | Heterobifunctional pan-selectin inhibitors | GlycoMimetics, Inc. | United Kingdom | EP1934236 | Current |
GG-GP487 | DRIVER PROFILING SYSTEM AND METHOD | MyDrive Solutions Limited | European (UK) | EP2619059 | Current |
GG-GP486 | Disc tumbler cylinder lock | Abloy OY | United Kingdom | EP2902569 | Current |
GG-GP485 | Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity | ViiV Healthcare Company & Shionogi & Co., Ltd. | United Kingdom | EP2465580 | Current |
GG-GP484 | Modulators of toll-like receptors | Gilead Sciences, Inc. | United Kingdom | EP2364314 | Current |
GG-GP483 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings LLC | United Kingdom | EP2253620 | Current |
GG-GP482 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. | United Kingdom | EP1603570 | Current |
GG-GP481 | Crystals including a malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof | Pharmacia & Upjohn Company LLC | United Kingdom | EP1419151 | Current |
GG-GP480 | Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent | Pfizer Products Inc. | United Kingdom | EP1945186 | Current |
GG-GP479 | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same | Wyeth LLC | United Kingdom | EP1902029 | Current |
GG-GP478 | Nucleoside phosphoramidate prodrugs | Gilead Pharmasset LLC | United Kingdom | EP2203462 | Current |
GG-GP477 | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | Incyte Corporation | United Kingdom | EP1696919 | Current |
GG-GP476 | Magnetic tunnel junction (mtj) and method for forming the same | Qualcomm Incorporated | United Kingdom | EP2419933 | Current |
GG-GP475 | Magnetic random access memory (mram) layout with uniform pattern | Qualcomm Incorporated | United Kingdom | EP2625689 | Current |
GG-GP474 | On-chip low voltage capacitor-less low dropout regulator with q-control | Qualcomm Incorporated | United Kingdom | EP2564284 | Current |
GG-GP473 | Semi-persistent scheduling grants in heterogeneous networks | Qualcomm Incorporated | United Kingdom | EP2561713 | Current |
GG-GP472 | Adaptive resource negotiation between base stations for enhanced interference coordination | Qualcomm Incorporated | United Kingdom | EP2559291 | Current |
GG-GP471 | Cqi estimation in a wireless communication network | Qualcomm Incorporated | United Kingdom | EP2559182 | Current |
GG-GP470 | Feedback of control information for multiple carriers | Qualcomm Incorporated | United Kingdom | EP2556618 | Current |
GG-GP469 | System and method to read and write data at a magnetic tunnel junction element | Qualcomm Incorporated | United Kingdom | EP2382633 | Current |
GG-GP468 | Word line voltage control in stt-mram | Qualcomm Incorporated | United Kingdom | EP2353164 | Current |
GG-GP467 | Low output skew double data rate serial encoder | Qualcomm Incorporated | United Kingdom | EP2055008 | Current |
GG-GP466 | Code division multiplexing in a single-carrier frequency division multiple access system | Qualcomm Incorporated | United Kingdom | EP1922830 | Current |
GG-GP465 | Transmit spatial diversity for cellular single frequency networks | Qualcomm Incorporated | United Kingdom | EP1894317 | Current |
GG-GP464 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | Viv Healthcare Company & Shionogi & Co, Ltd | United Kingdom | EP1874117 | Current |
GG-GP463 | 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer | ASTRAZENECA AB | United Kingdom | EP2736895 | Current |
GG-GP462 | Animal identification system and related method | Chamberlain, Chamberlain & Smith | United States of America | US9,007,218 B2 | Current |
GG-GP461 | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP | United Kingdom | EP2485736 | Current |
GG-GP460 | Inhibitors of hepatitis c virus replication | MERCK SHARP & DOHME CORP. | United Kingdom | EP2410844 | Current |
GG-GP459 | Certain triazolopyrazines, compositions thereof and methods of use therefor | Hutchison Medipharma Limited | United Kingdom | EP2719699 | Current |
GG-GP458 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. | United Kingdom | EP2581078 | Current |
GG-GP457 | Tigecycline compositions and methods of preparation | WYETH LLC | United Kingdom | EP1858488 | Current |
GG-GP456 | Echinocandin pharmaceutical formulations containing micelle-forming surfactants | ELI LILLY & COMPANY | United KIngdom | EP1582204 | Current |
GG-GP455 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC | United Kingdom | EP2822954 | Current |
GG-GP454 | 3-((3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidinyl)-3-oxo-propionitrile as protein kinase inhibitor | PFIZER PRODUCTS INC. | United Kingdom | EP1666481 | Current |
GG-GP453 | Micronized CaCO3 slurry injection system for the remineralization of desalinated and fresh water | Omya International AG | United Kingdom | EP2548848 | Current |
GG-GP452 | Inhalation composition containing aclidinium for treatment of chronic obstructive pulmonary disease | ALMIRALL S.A. | United Kingdom | EP2265257 | Current |
GG- GP451 | Dibenzothiazepine derivative and use thereof | ASTRAZENECA AB | The European Patent Office | EP2307389 | Current |
GG-GP450 | Intrauterine deposit | MERCK SHARP & DOHME B.V. | European (UK) | EP2211794 | Current |
GG-GP449 | Non-nucleoside reverse transcriptase inhibitors | MERCK CANADA INC. | United Kingdom | 2552902 | Current |
GG- GP448 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | ALMIRALL S.A. | United Kingdom | 2774623 | Current |
GG- GP447 | Vaccine comprising an oil in water emulsion adjuvant | GLAXOSMITHKLINE BIOLOGICALS S.A. | United Kingdom | EP2086582 | Current |
GG- GP446 | Chromenone derivatives with anti -tumour activity | ASTRAZENECA AB | United Kingdom | 2493870 | Current |
GG-GP445 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842 | ASTRAZENECA AB | United Kingdom | EP2167502 | Current |
GG- GP444 | Pyrazinone derivatives and their use in the treatment of lung diseases | ASTRAZENECA AB | United Kingdom | EP2170848 | Current |
GG- GP443 | Novel pyrrolo [3, 2-d]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB | United Kingdom | EP1824855 | Current |
GG- GP442 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. | United Kingdom | EP2049506 | Current |
GG- GP441 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES, INC. | United Kingdom | EP1301519 | Current |
GG- GP440 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB | The European Office | EP1966158 | Current |
GG- GP439 | Morpholino pyrimidines and their use in therapy | ASTRAZENECA AB | United Kingdom | EP2579877 | Current |
GG- GP438 | Substituted diazepan compounds as orexin receptor antagonists | MERCK SHARP & DOHME CORP. | United Kingdom | EP2089382 | Current |
GG-GP437 | Beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. | The European Patent Office | 2666774 | Current |
GG-GP436 | Relocation in a communication system | VRINGO INFRASTRUCTURE, INC. | United Kingdom | EP1212919 | Current |
GG-GP435 | Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors | ASTRAZENECA AB | United Kingdom | EP2201012 | Current |
GG-GP434 | Novel hydrogen sulfate salt | [1] ARRAY BIOPHARMA, INC. [2] ASTRAZENECA AB | The European Patent Office | EP1968948 | Current |
GG-GP433 | Composition for inhibition of cathepsin k | [1] Merk Sharp & Dohme Corp & [2] Merck Canada Inc. | United Kingdom | 1855674 | Current |
GG-GP432 | Heterocyclic compounds that are active as beta lactamase inhibitors | ASTRA ZENECA HOLDING FRANCE | United Kingdom | UK 2279737 | Current |
GG-GP431 | 1-alkoxy 1h-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY | United Kingdom | 1789042 | Current |
GG-GP430 | Humanized antibodies that recognize beta amyloid peptide | JANSSEN SCIENCES IRELAND UC and WYETH LLC | United Kingdom | EP1636268 | Current |
GG-GP429 | Monodisperse pegylated naloxol compositions | NEKTAR THERAPEUTICS | United Kingdom | EP1694363 | Current |
GG-GP428 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION | United Kingdom | 1966202 | Current |
GG-GP427 | Multivalent pneumococcal polysaccharide-protein conjugate composition | WYETH LLC | United Kingdom | 1868645 | Current |
GG-GP426 | Inhalation device for drugs in powder form | AstraZeneca AB | United Kingdom | 2063940 | Current |
GG-GP425 | Antibodies to human Programmed Death Receptor | Merck Sharp & Dohme B.V. | United Kingdom | 2170959 | Current |
GG-GP424 | Freeze-dried dosage form containing ondansetron | Glaxosmithkline Inc. | United Kingdom | 2295318 | Current |
GG-GP423 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | Pfizer Inc. | United Kingdom | EP2334687 | Current |
GG-GP422 | AMINO-HETEROCYCLIC COMPOUNDS | Pfizer Inc. | United Kingdom | EP2152712 | Current |
GG-GP421 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB | The European Patent Office | EP1809624 | Current |
GG-GP420 | Oxyntomodulin analogs | A) MERCK SHARP & DOHME CORP. B) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE C) INDIANA UNIVERSITY RESEARCH&TECHNOLOGY CORPORATION | United Kingdom | EP2398483 | Current |
GG-GP419 | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | United Kingdom | EP2358717 | Current |
GG-GP418 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC | United Kingdom | EP1746999 | Current |
GG-GP417 | N- (1, 1, 1, 3, 3, 3-hexafluoro-2-hydroxypropan-2-yl) benzyl-n' -arylcarbonylpiperaz ine derivatives as lxr modulators | MERCK SHARP & DOHME B.V. | United Kingdom | EP2297118 | Current |
GG-GP416 | Pyrido-, pyrazo- and pyrimidopyrimidine derivatives as mTOR inhibitors | KuDOS PHARMACEUTICALS LTD | United Kingdom | EP1954699 | Current |
GG-GP415 | 8a-azalides as veterinary antimicrobial agents | MERCK SHARP & DOHME CORP. | The European Patent Office | 1510214 | Current |
GG-GP414 | Anacetrapib and other cetp inhibitprs | MERCK SHARP & DOHME CORP. | The European Patent Office | 1765793 | Current |
GG-GP413 | LIVE ATTENUATED ROTAVIRUS VACCINE FOR ORAL ADMINISTRATION | GLAXOSMITHKLINE BIOLOGICALS S.A. | The European Patent Office | 1863526 | Current |
GG-GP412 | Tricyclic compounds and their use as glucocorticoid receptor modulators | Pfizer Products Inc. | The European Patent Office | 2114970 | Current |
GG-GP411 | STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE | UCB PHARMA GMBH | The European Patent Office | 2029134 | Current |
GG-GP410 | New crystalline and amorphous form of a triazolo (4,5-D)pyrimidine compound | Astrazeneca AB | The European Patent Office | 1493745 | Current |
GG-GP409 | Screed comprising recycled glass waste | Ecoscreed Holdings Limited | The European Patent Office | EP 1 622847 | Current |
GG-GP408 | A method of laying a floor covering | !OBAC Limited | The European Patent Office | EP1768527 | Current |
GG-GP407 | 3-aminocyclopentanecarboxamides as chemokine receptor modulators | Pfizer Inc | The European Patent Office | EP2370442 | Current |
GG-GP406 | Pharmaceutical composition 271 | A) Astrazeneca AB B) Array Biopharma, Inc. | The European Patent Office | EP2271321 | Current |
GG-GP405 | Tricyclic compounds and their use as glucocorticoid receptor modulators | Pfizer Products Inc. | The European Patent Office | EP2114888 | Current |
GG-GP404 | Therapeutic formulation for administering tolterodine with controlled release | Pfizer Health AB | The European Patent Office | EP1039882 | Current |
GG-GP403 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | Pfizer Inc. | The European Patent Office | EP1784396 | Current |
GG-GP402 | Tricyclic nitrogen containing compounds as antibacterial agents. | Glaxo Group Limited | The European Patent Office | EP2137196 | Current |
GG-GP401 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | PANMIRA PHARMACEUTICALS,LLC | The European Patent Office | 1943219 | Ceased |
GG-GP400 | Use of mammalian cytokine-related reagents | MERCK SHARP & DOHME CORP | The European Patent Office | 2311869 | Current |
GG-GP399 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3 YL) BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT, INC | The European Patent Office | EP 2 182 949 | Current |
GG-GP398 | 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibiting activity | Pfizer Limited | The European Patent Office | EP 1 689 751 | Current |
GG-GP397 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. | United Kingdom | EP1320531 | Ceased |
GG-GP396 | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors | A) Merck Sharp & Dohme Corp B) MSD Italia S.R.L | The European Patent Office | EP 2 310 095 | Current |
GG-GP395 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP | The European Patent Office | EP 2 358 686 | Current |
GG-GP394 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB | The European Patent Office | EP 2 125 748 | Current |
GG-GP393 | Underwater power generator | Rotech Holdings Limited | The European Patent Office | EP 2 122 160 | Current |
GG-GP392 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. | The European Patent Office | EP 1 973 545 | Current |
GG-GP391 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Inc | The European Patent Office | EP 1 841757 | Current |
GG-GP390 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA, INC | The European Patent Office | EP 1 660 090 | Current |
GG-GP389 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER, INC. | The European Patent Office | EP 1 786 785 | Current |
GG-GP388 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. | The European Patent Office | EP 1482932B1 | Current |
GG-GP387 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | AstraZeneca AB | The European Patent Office | EP 2086939 | Ceased |
GG-GP386 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED | The European Patent Office | EP 1 924 570 | Ceased |
GG-GP385 | NOVEL HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA+LACTAMASES | Astra Zeneca Holding France SAS | The European Patent Office | EP 1 480 644 B1 | Current |
GG-GP384 | PREPARATION OF PREGABALIN AND RELATED COMPOUNDS | WARNER-LAMBERT COMPANY LLC | The European Patent Office | EP 1 831 154 | Current |
GG-GP383 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. | The European Patent Office | EP1856135 | Ceased |
GG-GP382 | Time-based modeling | Brixx International Limited | United States Of America | 6360188 | Current |
GG-GP381 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation | The European Patent Office | EP 1490064 | Current |
GG-GP380 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp | The European Patent Office | EP 2276756 | Current |
GG-GP379 | STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | UCB Pharma GmbH | The European Patent Office | EP1230209 | Current |
GG-GP378 | METHOD FOR ENZYMATIC PREPARATION OF (S) - 3 - CYANO -5 - METHYLHEXANOIC ACID | Pfizer Products Inc. | The European Patent Office | EP1745136 | Current |
GG-GP377 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB | United Kingdom | 2094694 | Ceased |
GG-GP376 | PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)DERIVATIVE USED AS PDE5 INHIBITORS | PFIZER PRODUCTS INC | The European Patent Office | EP1948661 | Current |
GG-GP375 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | a) PFIZER LIMITED b) PFIZER INC. | The European Patent Office | EP1620437 | Current |
GG-GP374 | 4 - Anilno Quinazoline Derivatives AS Antiproliferative Agents | AstraZeneca AB | The European Patent Office | EP 1 487 806 | Current |
GG-GP373 | POWER GENERATING APPARATUS WITH WATER TURBINE WITH BI-SYMMETRIC AIRFOIL | Rotech Holdings Limited | United Kingdom | EP1886015B | Current |
GG-GP372 | 1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE HYDRAZINO -2'-HYDROXY- 1,1'-BIPHENYL -3-CARBOXYLIC ACID | SMITHKLINE BEECHAM CORPORATION | The European Patent Office | EP1534390 | Current |
GG-GP371 | AN ANTIBODY SPECIFIC FOR SOLUBLE BAFF FOR USE IN THE TREATMENT OF CANCER | BIOGEN IDEC MA INC | The European Patent Office | EP1415659 | Ceased |
GG-GP370 | CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED | The European Patent Office | EP1928821 | Current |
GG-GP369 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp | The European Patent Office | EP1966151B1 | Ceased |
GG-GP367 | Neuromuscular Blocking agents | THE WELLCOME FOUNDATION LIMITED | United Kingdom | GB2 260 763 B | Expired |
GG-GP366 | A NOVEL POLYMORPHIC CRYSTALLINE FORM OF FLUTICASONE PROPIONATE, A METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLAXO GROUP LIMITED | The European Patent Office | EP 0 937 100 B1 | Ceased |
GG-GP365 | METERED DOSE INHALER FOR SALMETEROL | SMITHKLINE BEECHAM CORPORTATION | The European Patent Office | EP 0 820 323 B1 | Revoked |
GG-GP364 | CRYSTALLINE R-(R*R*)]-2(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN) | WARNER-LAMBERT COMPANY | The European Patent Office | EP 0 848 705 B1 | Revoked |
GG-GP363 | USE OF ACTIVITY INHIBITING DIPETIDYL PEPTIDASE IV EFFECTORS FOR LOWERING THE BLOOD GLUCOSE LEVEL IN MAMMALS | PROSIDION LIMITED | The European Patent Office | EP 0 896 538 B1 | Revoked |
GG-GP362 | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R- (R*,R*)]-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1) | WARNER-LAMBERT COMPANY | The European Patent Office | EP 0 839 132 B1 | Revoked |
GG-GP361 | METHOD FOR PREVENTING OR DELAYING CATHERTER-BASED REVASCULARIZATION | WARNER-LAMBERT COMPANY LLC | The European Patent Office | EP 1 117 392 B1 | Revoked |
GG-GP360 | (R-(R*,R*)) - 2 - (4 - FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYL-ETHYL-3-PHENYL-4-((PHENYLAMINO)-CARBONYL)-1H-PYRROLE-1-HEPTANOIC ACID, ITS LACTONE FORM AND SALTS THEREOF | WARNER-LAMBERT COMPANY | The European Patent Office | EP 0 409 281 B1 | Revoked |
GG-GP359 | Modafinil composition of defined particle size | Cephalon, Inc. | United Kingdom | GB 2 293 103 B | Revoked |
GG-GP358 | 7-(2-AMINOETHYL)-BENZOTHIAZOLONES | ASTRAZENECA AB | The European Patent Office | EP 0649418B1 | Ceased |
GG-GP357 | 1,2,5,6-Tetrahydropyridine-3-Carboxaldehyde Oxime Derivatives, process for their preparation, compositions containing them and their use as medicines | ROUSSEL-UCLAF | The European Patent Office | EP 0 239 445 B1 | Ceased |
GG-GP356 | VALACICLOVIR TABLETS CONTAINING COLLOIDAL SILICON DIOXIDE | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 806 943 B1 | Ceased |
GG-GP355 | Medicaments for treating Gastrointestinal disorders | GLAXO GROUP LIMITED | United Kingdom | GB 2259647 | Ceased |
GG-GP354 | Process for preparing aryl-piperidine Carbinols | BEECHAM GROUP PLC | The European Patent Office | EP 0 300 617 B1 | Ceased |
GG-GP353 | INDOLE DERIVATIVES | GLAXO SpA | United Kingdom | GB2 266 091 | Ceased |
GG-GP352 | Pharmaceutical compositions containing furan derivatives | GLAXO GROUP LIMITED | United Kingdom | GB 2 248 185 B | Ceased |
GG-GP351 | Attendance registration system by radio link | ALI GURYEL | The European Patent Office | EP 0 664 061 B1 | Ceased |
GG-GP350 | Film-coated solid dosage form of anti-migraine drug | GLAXO GROUP LIMITED | United Kingdom | GB 2 254 784 B | Ceased |
GG-GP349 | Preparation of Clavulanic Acid | SMITHKLINE BEECHAM PLC | United Kingdom | GB 2 287 026B | Ceased |
GG-GP348 | Window Restricting Device | SECURISTYLE LIMITED | United Kingdom | GB 2246393 B | Ceased |
GG-GP347 | Recombinant 21 KD Cocoa Protein and Precursor | MARS UK LIMITED | United Kingdom | GB 2260327 | Ceased |
GG-GP346 | 47kD and 31 kD cocoa bean proteins and a 67 kD precursor therefor | MARS UK LIMITED | United Kingdom | GB 2260328 | Ceased |
GG-GP345 | Improvements in cladding | SOLAGLAS LIMITED | United Kingdom | GB 2227270 B | Ceased |
GG-GP344 | Pyrazolopyrimidinones for the treatment of impotence | PFIZER LIMITED | The European Patent Office | EP 0 702 555 B1 | Revoked |
GG-GP343 | USE OF MOMETASONE FLOURATE FOR TREATING AIRWAY PASSAGE AND LUNG DISEASES | Merck Sharp & Dohme Corp | The European Patent Office | EP 2 156 840 B1 | Ceased |
GG-GP342 | DISC TUMBLER CYLINDER LOCK AND KEY COMBINATION | ABLOY OY | The European Patent Office | EP 2 029 839 B1 | Current |
GG-GP341 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LIMITED | The European Patent Office | EP 1 778 686 B9 | Current |
GG-GP340 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERES THEREOF | MERCK SHARP & DOHME CORP | The European Patent Office | EP 1 599 469 B1 | Ceased |
GG-GP339 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC | The European Patent Office | EP 1 519 939 B9 | Ceased |
GG-GP338 | USE OF MOMETASONE FLOURATE FOR TREATING AIRWAY PASSAGE AND LUNG DISEASES | Merck Sharp & Dohme Corp | The European Patent Office | EP 1 174 138 B1 | Ceased |
GG-GP336 | ANDROSTENONE DERIVATIVE | GLAXO WELLCOME INC. | The European Patent Office | EP 0 719 278 B1 | Expired |
GG-GP335 | Electrode Structure | FORCE TECHNOLOGY | United Kingdom | GB 2306973 | Ceased |
GG-GP334 | SUGAR-SUBSTITUTED 2-AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | Merck Sharp & Dohme Corp | The European Patent Office | EP 1 347 987 B1 | Current |
GG-GP333 | SUGAR-SUBSTITUTED 2-AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | Merck Sharp & Dohme Corp | The European Patent Office | EP 0 877 750 B1 | Ceased |
GG-GP332 | ANIMAL ACCESS SYSTEM | DAVID CHAMBERLAIN | United Kingdom | GB 2 381 180 B | Ceased |
GG-GP331 | SLIDING SASH WINDOWS | VENTROLLA LIMITED | United Kingdom | GB2276904 | Ceased |
GG-GP329 | THF-CONTAINING SULFONADE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | The European Patent Office | EP 0 846 110 B1 | Current |
GG-GP328 | CARBOCYCLIC NUCLEOSIDE HEMISULFATE AND ITS USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED | United Kingdom | GB 2 340 491 | Current |
GG-GP327 | HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | Merck Sharp & Dohme Corp | The European Patent Office | EP 0 720 599 B1 | Expired |
GG-GP326 | LIQUID COMPOSITION CONTAINING ONDANSETRON | GLAXOSMITHKLINE INC. | United Kingdom | GB 2295317B | Current |
GG-GP325 | METHOD OF TREATING ANDROGENIC ALOPECIA WITH 5-ALPHA REDUCTASTE INHIBITORS | Merck Sharp & Dohme Corp | The European Patent Office | EP 0 724 444 B1 | Expired |
GG-GP324 | ELECTROCHEMICAL TREATMENT OF REINFORCED CONCRETE | ATRAVERDA LIMITED | The European Patent Office | EP 1 055 017 B1 | Ceased |
GG-GP323 | Modafinil having defined particle size | Cephalon, Inc. | The European Patent Office | EP0731698 B1 | Ceased |
GG-GP322 | SASH WINDOW PARTING BEADS | VENTROLLA LIMITED | United Kingdom | GB2314578 | Ceased |
GG-GP321 | IMPROVEMENTS IN OR RELATING TO BEVERAGES | ROBINSONS SOFT DRINKS LIMITED | United Kingdom | GB2312606 B | Ceased |
GG-GP320 | IMPROVEMENTS IN OR RELATING TO BEVERAGES | ROBINSONS SOFT DRINKS LIMITED | United Kingdom | GB2298350 B | Ceased |
GG-GP319 | Synthesis of n-acetyl neuraminic acid derivatives | BIOTA SCIENTIFIC PTY LTD | The European Patent Office | EP 0 662 967 B1 | Expired |
GG-GP318 | Plastics piping | HEPWORTH BUILDING PRODUCTS LIMITED | United Kingdom | GB2289108 | Ceased |
GG-GP317 | PYRIMIDINE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS | SHIONOGI SEIYAKU KABUSHIKI KAISHA | The European Patent Office | EP 0 521 471 B1 | Current |
GG-GP316 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ASTRA ZENECA AB | The European Patent Office | EP 0 579 826 B1 | Expired |
GG-GP315 | PRODRUGS OF THROMBIN INHIBITORS | ASTRAZENECA AB | The European Patent Office | EP 0 995 755 B1 | Ceased |
GG-GP314 | Stable Oral CI-981 Formulation and Process of preparing same | WARNER-LAMBERT COMPANY | The European Patent Office | EP 0680 320 B1 | Ceased |
GG-GP313 | ELECTROCHEMICAL METHOD AND ELECTRODE | ATRAVERDA LIMITED | The European Patent Office | EP 0 883 700 B1 | Ceased |
GG-GP312 | CRYSTALLINE N-ACETYL NEURAMINIC ACID DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | BIOTA SCIENTIFIC PTY LTD | The European Patent Office | EP 0734382 B1 | Expired |
GG-GP311 | SLOT DRAIN | ALUMASC LIMITED | United Kingdom | GB2388144B | Ceased |
GG-GP310 | Detection of multiple articles | BTG INTERNATIONAL LIMITED | The European Patent Office | EP 0598624 | Ceased |
GG-GP309 | FLUTICASONE PROPIONATE FORMULATIONS | GLAXO WELLCOME AUSTRALIA LTD | The European Patent Office | EP 0 760 649 B1 | Expired |
GG-GP308 | MEDICAMENTS | GLAXO GROUP LIMITED | The European Patent Office | EP 0 616 523 B1 | Ceased |
GG-GP307 | COMBINATION OF ATOVAQUONE WITH PROGUANIL FOR THE TREATMENT OF PROTOZOAL INFECTIONS | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 670 719 B1 | Expired |
GG-GP306 | Transmission network | NORWEB PLC | United Kingdom | GB2 272 350 | Ceased |
GG-GP305 | Transmission network and filter therefor | NORWEB PLC | United Kingdom | GB2 304 013 | Ceased |
GG-GP304 | QUINAZOLINE DERIVATIVES | Astrazeneca AB | The European Patent Office | EP 0 823 900 | Ceased |
GG-GP303 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ASTRAZENECA AB | The European Patent Office | EP 0 832 082 B1 | Ceased |
GG-GP302 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LIMITED | The European Patent Office | EP 0 958 277 B1 | Ceased |
GG-GP301 | AMIDINO DERIVATIVES AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 618 898 B1 | Ceased |
GG-GP300 | Modafinil having defined particle size | Cephalon, Inc. | The European Patent Office | EP 0 966962 B1 | Ceased |
GG-GP299 | Advertising Fitting | ESCALATOR ADVERTISING LIMITED | United Kingdom | GB2269150 | Ceased |
GG-GP298 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | The European Patent Office | EP 0 659 181 B1 | Expired |
GG-GP297 | FREEZE-DRIED DOSAGE FORM CONTAINING ONDANSETRON | GLAXO WELLCOME INC. | United Kingdom | GB2295318B | Ceased |
GG-GP296 | CRYSTALLINE FORMS OF Et02C-CH2-(R)Cgl-Aze-Pab-OH | ASTRAZENECA AB | The European Patent Office | EP 1 107 980 B1 | Ceased |
GG-GP295 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC | The European Patent Office | EP 0 658 161 B1 | Ceased |
GG-GP294 | CORD LOCKING DEVICES AND SASH WINDOW PARTING BEADS | VENTROLLA LIMITED | United Kingdom | GB2298892 | Ceased |
GG-GP293 | PAROXETINE HYDROCHLORIDE ANHYDRATE SUBSTANTIALLY FREE OF BOUND ORGANIC SOLVENT | SMITHKLINE BEECHAM PLC | United Kingdom | GB 2 297 550 B | Ceased |
GG-GP291 | ONDANSETRON FOR RECTAL ADMINISTRATION | LABORATORIES GLAXO SA | United Kingdom | GB2279008B | Ceased |
GG-GP290 | Substituted Pyrazolyl Benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO | The European Patent Office | EP 0 731 795 B1 | Expired |
GG-GP289 | SUSTAINED RELEASE TABLETS CONTAINING BUPROPION | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 656 775 B1 | Ceased |
GG-GP288 | Magnifying Spectacles | MARJORIE ANNE MOYSE | United Kingdom | GB 2317966 | Ceased |
GG-GP287 | Process for the preparation of N-Acetyl Neuraminic Acid Derivatives | BIOTA SCIENTIFIC PTY LTD | The European Patent Office | EP 0 705 256 B1 | Expired |
GG-GP286 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB | The European Patent Office | EP 1 154 774 B1 | Current |
GG-GP285 | PYRROLO 2,3-d] PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC | The European Patent Office | EP 1 087 971 B1 | Ceased |
GG-GP284 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC | The European Patent Office | EP 1 084 114 B1 | Ceased |
GG-GP283 | VACCINE AGAINST HUMAN PAPILLOMAVIRUS (TYPES 18) | UNIVERSITY OF QUEENSLAND | The European Patent Office | EP 1359 156 B1 | Expired |
GG-GP282 | TRIAZOLYL TROPANE DERICATIVES AS CCR5 MODULATORS | PFIZER LIMITED | The European Patent Office | EP 1 284 974 B1 | Current |
GG-GP281 | TRICYCLIC INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS INC | The European Patent Office | EP 1 140 936 B1 | Ceased |
GG-GP280 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER-LAMBERT COMPANY LLC | The European Patent Office | EP 1 250 311 B1 | Ceased |
GG-GP279 | PYRROLO 2,3-d] PYRIMIDINE COMOUNDS | PFIZER PRODUCTS INC | The European Patent Office | EP 1 087 970 B1 | Ceased |
GG-GP278 | IMPROVEMENTS IN OR RELATING TO BEVERAGES | ROBISONS SOFT DRINKS LIMITED | United Kingdom | GB 2 312 606 B | Ceased |
GG-GP277 | IMPROVEMENTS IN OR RELATING TO BEVERAGES | ROBISONS SOFT DRINKS LIMITED | United Kingdom | GB 2 298 350 B | Ceased |
GG-GP276 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB | The European Patent Office | EP 1 242 364 B1 | Ceased |
GG-GP275 | INK CARTRIDGE FOR INK-JET PRINTING APPARATUS | SEIKO EPSON CORPORATION | United Kingdom | GB 2 369 801 B | Current |
GG-GP274 | INK TANK CATRIDGE AND CONTAINER THEREFOR | Seiko Epson Corportation | The European Patent Office | EP 0 553 535 B2 | Expired |
GG-GP273 | INK TANK CATRIDGE AND CONTAINER THEREFOR | Seiko Epson Corportation | The European Patent Office | EP 1 013 444 B1 | Expired |
GG-GP272 | INK SUPPLY UNIT | Seiko Epson Corporation | The European Patent Office | EP 1 016 533 B1 | Current |
GG-GP271 | INK CATRIDGE AND RECORDING APPARATUS | Seiko Epson Corporation | United Kingdom | GB 2 395 684 B | Current |
GG-GP270 | INK CATRIDGE AND INK-JET RECORDING APPARATUS | Seiko Epson Corporation | The European Patent Office | EP 1 247 650 B1 | Ceased |
GG-GP269 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB | The European Patent Office | EP 1 135 391 B1 | Current |
GG-GP268 | PHOSPHODIESTRERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | LILLY Icos LLC | The European Patent Office | EP 1 173 181 B1 | Current |
GG-GP267 | INCLUSION COMPLEXES OF ARYL-HETEROCYCLIC SALTS | PFIZER INC | The European Patent Office | EP 0 900 088 B1 | Current |
GG-GP266 | PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS | PFIZER PRODUCTS INC | The European Patent Office | EP 1 235 830 B1 | Current |
GG-GP265 | STRUCTURE AND METHOD FOR JOINING PARTS | PFIZER HEALTH AB | The European Patent Office | EP 0 965 002B1 | Current |
GG-GP264 | ACRIDINE DERIVATIVE FOR INCREASING THE BIOAVAILABILITY OF TAXOL | GLAXO GROUP LIMITED | The European Patent Office | EP 1 009 436 B1 | Ceased |
GG-GP263 | NEW FORMULATION FOR INHILATION HAVING A POURED BULK DENSITY OF FROM 0.28 TO 0.38 G/ML, A PROCESS FOR PREPARING THE FORMULATION AND USE THEREOF | ASTRAZENECA AB | The European Patent Office | EP 1 007 017 B1 | Current |
GG-GP262 | NEW FORMULATION FOR INHILATION HAVING A POURED BULK DENSITY OF FROM 0.28 TO 0.38 G/ML, COMPRISING FORMOTEROL | ASTRAZENECA AB | The European Patent Office | EP 1 009 394 B1 | Current |
GG-GP261 | QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.p.A. | The European Patent Office | EP 0 804 419 B1 | Ceased |
GG-GP259 | THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS ANTIDIABETIC | SMITHKLINE BEECHAM PLC | The European Patent Office | EP 1 173 434 B1 | Ceased |
GG-GP258 | 2, 3-DIARYL-PYRAZOLO (1,5-B) PYRIDAZINES DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LIMITED | The European Patent Office | EP 1 032 575 B1 | Ceased |
GG-GP257 | FORMULATION | ASTRAZENECA AB | United Kingdom | GB 2 359 254 B | Current |
GG-GP256 | Swallow Tablet Comprising Paracetamol | GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENTS (IRELAND) (NO.2) | The European Patent Office | EP 0 981 334 B1 | Current |
GG-GP255 | Quinoline Derivatives as NK3 Antagonists | GlaxoSmithKline S.p.A | The European Patent Office | EP 0 874 827 B1 | Ceased |
GG-GP254 | Process for the Synthesis of HIV Protease Inhibitors | GLAXO GROUP LIMITED | The European Patent Office | EP 1 066 276 B1 | Ceased |
GG-GP253 | GAMES AND GAME APPARATUS | DEREK JOHN WEBB and HANNAH SARAH O'DONNELL in partnership as Prime Table Games UK | United Kingdom | GB 2291360 B | Ceased |
GG-GP252 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GlaxoSmithKline LLC | The European Patent Office | EP 1 047 694 B1 | Current |
GG-GP251 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED | The European Patent Office | EP 1 098 898 B1 | Current |
GG-GP248 | METHOD FOR REMOVING SURFACE COATINGS | FARROW SYSTEM LLIMITED | United Kingdom | GB 2 344 348 | Ceased |
GG-GP247 | EXO-S-MECAMYLAMINE FORMULATION | UNIVERSITY OF SOUTH FLORIDA | The European Patent Office | EP 1 634 498 B1 | Current |
GG-GP246 | TRIAZOLYL TROPANE DERICATIVES AS CCR5 MODULATORS | PFIZER LIMITED | The European Patent Office | EP 1 526 134 B1 | Current |
GG-GP245 | 1,2,3,4-TETRASUBSTITUTED INDOLE FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB | The European Patent Office | EP 1 656 346 B1 | Ceased |
GG-GP244 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB | The European Patent Office | EP 1 686 999 B1 | Current |
GG-GP243 | REDUCTION OF DIZZINESS, A SIDE EFFECT ASSOCIATED WITH PIRFENIDONE THERAPY | INTERMUNE, INC | The European Patent Office | EP 1 965 797 B1 | Current |
GG-GP242 | NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT INC | The European Patent Office | EP 2 094 703 B1 | Current |
GG-GP241 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC | The European Patent Office | EP 2 085 395 B1 | Ceased |
GG-GP240 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC | The European Patent Office | EP 1 730 119 B1 | Current |
GG-GP239 | TRICYCLIC THROMBIN RECEPTOR ANTAGONIST | SCHERING CORPORATION | The European Patent Office | EP 2 062 890 B1 | Current |
GG-GP238 | USE OF R- (+) -2-(3-DIISOPROYLAMINO-1-PHENYLPROPYL) -4-HYDROXY-METHYL-PHENYLISOBUTY RIC ACID ESTER HYDROGENFUMARATE FOR THE TREATMENT OF URINARY INCONTINENCE | UCB PHARMA GMBH | The European Patent Office | EP 1 690 536 B1 | Current |
GG-GP237 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE Receptors | GLAXO GROUP LIMITED | The European Patent Office | EP 1 646 613 B1 | Ceased |
GG-GP235 | VACCINE AGAINST ANTIGENS FROM BACTERIAE | GLAXOSMITHKLINE BOLOGICALS S.A. | The European Patent Office | EP 1 163 000 B1 | Ceased |
GG-GP234 | 6.ALPHA.,9.ALPHA.-DIFLUORO-17.ALPHA.-(2FURANYLCARBOXYL)OXY-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4-DIENE-17-CARBOTHIOIC ACIDS-FLUOROMETHYL ESTER AS AN ANTI_INFLAMMATORY AGENT. | GLAXO GROUP LIMITED | The European Patent Office | EP 1 305 329 B1 | Current |
GG-GP233 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC | The European Patent Office | EP 1 044 189 B1 | Current |
GG-GP232 | PHARAMACEUTICAL COMPOSITION CONTANING PROTON PUMP INHIBITORS | Merck Sharp & Dohme Corp | The European Patent Office | EP 0 819 004 B1 | Ceased |
GG-GP231 | USE OF ROSUVASTATIN (ZD-4522) IN THE TREATMENT OF HETEROZYGOUS FAMILIALHYPERCHOLESTEROLEMIA | ASTRAZENECA AB | The European Patent Office | EP 1 339 409 B1 | Current |
GG-GP230 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED | The European Patent Office | EP 1 425 001 B1 | Current |
GG-GP229 | VACCINES AGAINST CANCERS | GLAXOSMITHKLINE BOLOGICALS S.A. | The European Patent Office | EP 1 326 638 B1 | Current |
GG-GP228 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp | The European Patent Office | EP 1 924 593 B1 | Ceased |
GG-GP227 | Medical use of tetrahydrotriazolo[4.3-a]pyrazine | Merck Sharp & Dohme Corp | The European Patent Office | EP 1 625 847 B1 | Ceased |
GG-GP226 | ANTIBODIES AGAINST AMYLOID-BETA PEPTIDE | GLAXO GROUP LIMITED | The European Patent Office | EP 1 996 621 B1 | Ceased |
GG-GP225 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | The European Patent Office | EP 1 294 378 B1 | Current |
GG-GP224 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTIEN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC | The European Patent Office | EP 1 218 348 B1 | Current |
GG-GP223 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEOTIR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMATION | PFIZER LIMITED | The European Patent Office | EP 1 682 545 B1 | Current |
GG-GP222 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER PRODUCTS INC | The European Patent Office | EP 1 708 991 B1 | Ceased |
GG-GP221 | Compositions containing pyrrolo -2,3-d pryrimidine derivatives | PFIZER PRODUCTS INC | The European Patent Office | EP 1 382 339 B1 | Current |
GG-GP220 | PYRROLE SUBSTITUED 2-INDOLINONE PROTEIN KINASE INHIBITORS | a) PHARMACIA & UPJOHN COMPANY LLC b) Sugen, Inc. | The European Patent Office | EP 1 255 752 B1 | Current |
GG-GP219 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED | The European Patent Office | EP 1 708 992 B1 | Ceased |
GG-GP218 | EXO-S-MECAMYLAMINE FORMULATION AND USE IN TREATMENT | UNIVERSITY OF SOUTH FLORIDA | The European Patent Office | EP 1 139 743 B1 | Ceased |
GG-GP217 | POWER GENERATOR AND TURBINE UNIT | ROTECH HOLDINGS LIMITED | The European Patent Office | EP 1 436 504 B1 | Current |
GG-GP216 | UNDERWATER POWER GENERATOR | ROTECH HOLDINGS LIMITED | United Kingdom | GB 2447514 B | Current |
GG-GP215 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC | The European Patent Office | EP 1 519 939 B1 | Ceased |
GG-GP214 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF CENTERAL NERVOS SYSTEM DISORDERS COMPRISING A NICOTINE ANALOG AND AN ACTYLCHOLINESTERASE INHIBITOR | TARGACEPT INC | The European Patent Office | EP 1 102 588 B1 | Ceased |
GG-GP213 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC | The European Patent Office | EP 1 678 172 B1 | Ceased |
GG-GP212 | 3-Substituted-2 (Arylalkyl)-1-Azabicycloalka and methods of use thereof | TARGACEPT INC | The European Patent Office | EP 1 594 869 B9 | Ceased |
GG-GP211 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC | The European Patent Office | EP 1 601 670 B1 | Current |
GG-GP210 | Adjuvant systems and vaccines | GLAXOSMITHKLINE BIOLOGICALS S.A. | The European Patent Office | EP 1 126 876 B1 | Ceased |
GG-GP209 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED | The European Patent Office | EP 1 377 556 B1 | Current |
GG-GP208 | IMMUNOSTIMULATORY NUCLEIC ACIDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | The European Patent Office | EP 1 221 955 | Ceased |
GG-GP207 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Holdings Ireland Unlimited Company | The European Patent Office | EP 1 427 415 B1 | Current |
GG-GP206 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | Axovant Sciences Ltd. | The European Patent Office | EP 1 497 266 B1 | Current |
GG-GP204 | INFLUENZA VACCINE COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS NIEDERLASSUNG DER SMITHKLINE BEECHAM PHARMA GmbH & CO. KG | The European Patent Office | EP 1 407 008 B1 | Ceased |
GG-GP203 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA S.R.L. | The European Patent Office | EP 1 406 899 B1 | Ceased |
GG-GP202 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | TEVA PHARMACEUTICALS INTERNATIONAL GMBH | The European Patent Office | EP 1 240 142 B1 | Current |
GG-GP201 | USE OF AN ANTAGONIST ANTIBODY TO THE INFLAMMATORY MEDIATOR ONCOSTATIN M (OSM) | GLAXO GROUP LIMITED | The European Patent Office | EP 1 071 449 B1 | Ceased |
GG-GP200 | PYRIMIDINE-4-ONE DERIVATIVE AS LDL-PLA2 INHIBITOR | Smithkline Beecham PLC | The European Patent Office | EP 1 263 740 B1 | Current |
GG-GP199 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC | The European Patent Office | EP 1 465 864 B1 | Ceased |
GG-GP198 | (S, S)-REBOXETINE FOR TREATING CHRONIC PAIN | PHARMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 196 172 B1 | Ceased |
GG-GP197 | HIGH DRUG LOAD TABLET | NOVARTIS AG, Incorporated in Switzerland | The European Patent Office | EP 1 501 485 B1 | Ceased |
GG-GP196 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG, Incorporated in Switzerland | The European Patent Office | EP 1 532 138 B1 | Current |
GG-GP195 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | AstraZeneca AB | The European Patent Office | EP 1 506 211 B1 | Current |
GG-GP194 | NEW FORMULATION | ASTRAZENECA AB | The European Patent Office | EP 1 000 079 B1 | Current |
GG-GP193 | WINDANGETRIEBENES WASSERFAHRZEUG | SKYSAILS GMBH & CO., KG | The European Patent Office | EP 1 409 339 B1 | Ceased |
GG-GP192 | THERAPEUTIC COMBINATIONS COMPRISING AMLODIPINE AND ATORVASTATIN | PFIZER PRODUCTS INC | The European Patent Office | EP 1 491 193 B1 | Ceased |
GG-GP190 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY LLC | The European Patent Office | EP 1 032 555 B1 | Ceased |
GG-GP189 | UNDERWATER DUCTED TURBINE | CLEAN CURRENT LIMITED PARTENERSHIP | The European Patent Office | EP 1 430 220B1 | Ceased |
GG-GP188 | IMMUNOSTIMULATORY NUCLEIC ACIDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION and COLEY PHARMACEUTICAL GMBH | The European Patent Office | EP 1 221 955 B9 | Ceased |
GG-GP187 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | The European Patent Office | EP 1 732 562 B1 | Ceased |
GG-GP186 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES, INC. | The European Patent Office | EP 0 957 929 B1 | Ceased |
GG-GP185 | ROPINIROLE-CONTAINING HYDROPHILIC/LIPHILIC POLYMERIC MATRIX DOSAGE FORMULATION | JAGOTEC AG | The European Patent Office | EP 1 272 167 B1 | Ceased |
GG-GP184 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | The European Patent Office | EP 1 558 582 B1 | Current |
GG-GP183 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB | The European Patent Office | EP 1 244 647 B1 | Current |
GG-GP182 | THERAPEUTIC BIARYL DERIVATIVES | GLAXO GROUP LIMITED | The European Patent Office | EP 1 087 943 B1 | Current |
GG-GP180 | Paving Block | Hanson Building Products Limited | United Kingdom | GB 2 338 969 B | Current |
GG-GP179 | CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO - (N+1) - ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | PHARMACIA CORPORTATION | The European Patent Office | EP 1 115 695 | Ceased |
GG-GP178 | (S,S) - REBOXETINE FOR TREATING FIBROMYALGIA AND OTHER SOMATOFORM DISORDERS | PHARMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 459 750 | Ceased |
GG-GP177 | Compounds affecting glucokinase | ASTRAZENECA AB | The European Patent Office | EP 1 529 530 B1 | Ceased |
GG-GP176 | OXIDATION PROCESS FOR PREPARING THE INTERMEDIATE 6.ALPHA.-DIFLURO-11.BETA.,17.ALPHA.-DIHYDROXY-16.ALPHA.-METHYL-ANDROST-1,4-DIEN-3-ONE17.BETA.-CARBOXYLIC ACID | GLAXO GROUP LIMITED | The European Patent Office | EP 1 301 526B1 | Ceased |
GG-GP175 | (S,S) - REBOXETINE FOR TREATING FIBROMYALGIA AND OTHER SOMATOFORM DISORDERS | PHARMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 459 750 B1 | Ceased |
GG-GP174 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORTATION | The European Patent Office | EP 1 294 378 B1 | Ceased |
GG-GP173 | (R)-CHIRAL HALOGENATED 1- SUBSTITUTEDAMINO-(N+1)- ALKANOLS USEFUL FOR INHIBITING COLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSATNO COMPANY | The European Patent Office | EP 1 115 695 B1 | Ceased |
GG-GP172 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORTATION | The European Patent Office | EP 1 265 860 B1 | Ceased |
GG-GP171 | RECONSTITUTABLE PARENERAL COMPOSITION CONTAINING A COX-2 INHIBITOR | PHARMACIA CORPORTATION | The European Patent Office | EP 1 372 645 B1 | Current |
GG-GP170 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC | The European Patent Office | EP 1 289 955 B1 | Ceased |
GG-GP169 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED | The European Patent Office | EP 1 366 033 B1 | Ceased |
GG-GP168 | PHTHALAZINONE DERIVATIVES | kuDOS Pharmaceuticals Limited | United Kingdom | GB 2 415 430 B | Current |
GG-GP167 | CRYSTALLINE DERIVATIVES OF 2- (5-CHLOROTHIEN-2-YL) -N- ((3S)-1((1S)-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLINDIN-YL) ETHENSULFONAMIDE | GLAXO GROUP LIMITED | The European Patent Office | EP 1 567 519 B1 | Ceased |
GG-GP166 | PROCESS FOR PREPARATION OF PYRAZOLO- (4,3-d) PYRIMIDIN-7-ONES AND INTERMEDIATES THEREOF | PFIZER LIMITED | The European Patent Office | EP 0 994115 B1 | Ceased |
GG-GP165 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HYPERPLASIA AND OTHER DISEASES | PHARMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 203 770 B1 | Expired |
GG-GP164 | STABLE SALTS OF NOVEL DERIVATIVES OF 3, 3-DIPHENYLPROPYLAMINES | SCHWARZ PHARAMA AG | The European Patent Office | EP 1 230 209 B1 | Ceased |
GG-GP163 | THERAPUTIC COMBINATIONS COMPRISING AMLODIPIN AND ATORVASTATIN | PFIZER PRODUCTS INC | The European Patent Office | EP 1 003 503 B1 | Ceased |
GG-GP162 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB | The European Patent Office | EP 1 240 172 B1 | Ceased |
GG-GP161 | PIPERAXINE COMPOUNDS AS TACHYKININS ANTAGONISTS | GLAXO GROUP LIMITED | The European Patent Office | EP 1 218 359 B1 | Current |
GG-GP160 | PYRAZOLO [4,3-D]PYRIMIDINE DERIVATIVES | PFIZER LIMITED | The European Patent Office | EP 1 220 856 B1 | Ceased |
GG-GP159 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | The European Patent Office | EP 1 411 881 B9 | Current |
GG-GP158 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED | The European Patent Office | EP 1 395 553 B1 | Ceased |
GG-GP157 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS INC | The European Patent Office | EP 0 889 036 B1 | Expired |
GG-GP156 | Inkjet recording apparatus and inkjet cartridge | SEIKO EPSON CORPORATION | United Kingdom | GB 2 406 544 B | Ceased |
GG-GP155 | ink cartridge for in jet recording apparatus | SEIKO EPSON CORPORATION | The European Patent Office | EP 0 715 958 B1 | Expired |
GG-GP154 | ink cartridge for in jet recording apparatus | SEIKO EPSON CORPORATION | The European Patent Office | EP 0 516 088 B1 | Expired |
GG-GP153 | A printing apparatus and ink cartridge therefore | SEIKO EPSON CORPORATION | United Kingdom | GB 2 411 863 B | Current |
GG-GP152 | Ink cartridge and ink cartridge holder | SEIKO EPSON CORPORATION | United Kingdom | GB 2 387 567 B | Current |
GG-GP151 | A printing apparatus and ink cartridge therefore | SEIKO EPSON CORPORATION | United Kingdom | GB 2 387 353 B | Current |
GG-GP150 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC | The European Patent Office | EP 1 028 961 B1 | Current |
GG-GP149 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED | The European Patent Office | EP 1 326 832 B1 | Ceased |
GG-GP148 | PROCESS FOR THE PREPARATION OF 3-OXO-4-AZASTEROIDS | GLAXO GROUP LIMITED | The European Patent Office | EP 1 335 930 B1 | Ceased |
GG-GP147 | NOVEL METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION | The European Patent Office | EP 1 135 128 B1 | Ceased |
GG-GP146 | ADJUVANT COMPOSITION COMPRISING SAPONIN AND AN IMMUNOSTIMULATORY OLIGONCLEOTIDE | GLAXOSMITHKLINE BIOLOGIVALS S.A. | The European Patent Office | EP 1 187 629 B1 | Ceased |
GG-GP145 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINE | SCHWARZ PHARMA AG | The European Patent Office | EP 1 077 912 B1 | Current |
GG-GP144 | PRINTER AND INK CARTRIDGE ATTACHED THERETO | SEIKO EPSON CORPORATION | The European Patent Office | EP 1 004 450 B1 | Current |
GG-GP143 | INK CATRIDGE ATTACHMENT/DETACHMENT DEVICE, RECORDING APPARATUS, LIQUID INJECTION APPARAUS, AND LIQUID CONTAINER | SEIKO EPSON CORPORATION | United Kingdom | GB 2 414 965 B | Ceased |
GG-GP142 | INK CATRIDGE ATTACHMENT/DETACHMENT DEVICE, RECORDING APPARATUS, LIQUID INJECTION APPARAUS, AND LIQUID CONTAINER | SEIKO EPSON CORPORATION | United Kingdom | GB 2 409 435 B | Ceased |
GG-GP141 | Inkjet recording apparatus and inkjet cartridge | SEIKO EPSON CORPORATION | United Kingdom | GB 2 391 200 B | Current |
GG-GP140 | INK CARTRIDGE AND PRINTER USING THE SAME | SEIKO EPSON CORPORATION | United Kingdom | GB 2 347 649 B | Current |
GG-GP139 | ANTIVIRAL COMBINATIONS CONTAINING NUCLEOSIDE ANALOGS | GLAXO GROUP LIMITED | The European Patent Office | EP0 513 917 B1 | Expired |
GG-GP138 | PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION | United Kingdom | GB 2157686 B | Ceased |
GG-GP137 | PHARMACEUTICAL COMPOSITIONS CONTAINING 1-HYDROXYPYRID-2-ONE DERIVATIVES | NATIONAL RESEARCH DEVELOPMENT CORPORATION | The European Patent Office | EP 0 138 420 B1 | Ceased |
GG-GP136 | OPTICAL TRANSMISSION SYSTEMS | THE PLESSEY COMPANY LIMITED | United Kingdom | GB 2086168 B | Ceased |
GG-GP135 | PCM COMMUNICATION SYSTEM | GEC PLESSEY TELECOMMUNICATIONS LTD | United Kingdom | GB2221125 B | Ceased |
GG-GP134 | DATA PATH PROTECTION | GEC PLESSEY TELECOMMUNICATIONS LTD | United Kingdom | GB2220329 B | Expired |
GG-GP133 | PCM COMMUNICATION SYSTEM | GEC PLESSEY TELECOMMUNICATIONS LTD | United Kingdom | GB2229610 B | Expired |
GG-GP132 | OPTICAL TRANSMISSION APPARATUS | GEC PLESSEY TELECOMMUNICATIONS LTD | United Kingdom | GB2233851 B | Expired |
GG-GP131 | HETEROCYCLIC DERIVATIVES | GLAXO GROUP LIMITED | United Kingdom | GB 2 220 937 | Expired |
GG-GP130 | ASSEMBLIES OF ELECTRICAL OR ELECTRONIC APPARATUS. | THE GENERAL ELECTRIC COMPANY P L C | United Kingdom | GB 2100522 | Ceased |
GG-GP129 | ASSEMBLIES OF ELECTRICAL OR ELECTRONIC APPARATUS | THE GENERAL ELECTRIC COMPANY P L C | United Kingdom | GB2100118 | Ceased |
GG-GP128 | DATA PROCESSING ARRANGEMENTS | THE GENERAL ELECTRIC COMPANY P L C | United Kingdom | GB 2099619 | Ceased |
GG-GP127 | Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments | GLAXO GROUP LIMITED | The European Patent Office | EP 0 226 266 B1 | Expired |
GG-GP125 | TRANSMISSIONS SYSTEMS | THE GENERAL ELECTRIC COMPANY P L C | United Kingdom | GB2145608 B | Expired |
GG-GP124 | Derivative of a n-phenylpyrazole | RHONE-POULENC AGRICULTURE LIMITED | The European Patent Office | EP 0295117 | Expired |
GG-GP123 | INDOLE DERIVATIVES | GLAXO GROUP LIMITED | United Kingdom | GB 2 208 646 | Expired |
GG-GP122 | NEW METHOD OF TRAFFIC CONTROL AND THE ROAD CONSTRUCTION ON THE CROSS SECTION OF A ROAD | YANG YIN-LUNG | United Kingdom | GB2202562 | Ceased |
GG-GP121 | ANTIBIOTIC M 139,603 FROM STREPTOMYCES LONGISPOROFLAVUS | IMPERIAL CHEMICAL INDUSTRIES PLC | United Kingdom | GB 2027013 | Ceased |
GG-GP120 | MEDICAMENTS | GLAXO GROUP LIMITED | United Kingdom | GB 2216414 | Expired |
GG-GP119 | DRUG ABSORBATES | GLAXO GROUP LIMITED | United Kingdom | GB 2218333 B | Ceased |
GG-GP118 | PHARMACEUTICAL FORMULATION CONTAINING PENCICLOVIR | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. | The European Patent Office | EP 0 511 991 B1 | Expired |
GG-GP117 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 434 450 B1 | Expired |
GG-GP116 | PHARMACOLOGICALLY ACTIVE CNS COMPOUNDS | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 372 934 B1 | Expired |
GG-GP113 | ELECTRICALLY-PROPELLED VEHICLE WITH INDIVIDUAL WHEEL DRIVE | ZF FRIEDRICHSHAFEN AKTIENGESELLSCHAFT | The European Patent Office | EP 1 511 646 | Ceased |
GG-GP112 | PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION | United Kingdom | GB 2136807B | Expired |
GG-GP111 | Therapeutic heterocyclic compounds | ZENECA LIMITED | The European Patent Office | EP 0 486 666 B1 | Expired |
GG-GP110 | MOTORIC DEVICE FOR DIGGING TRENCHES IN THE SOIL WITH THE AID OF ROTARY CUTTERS | SOLETANCHE SOCIÉTÉ ANONYME DITE | The European Patent Office | EP 0 253 726 | Ceased |
GG-GP109 | Derivatives and analogues of 2-Deoxy-2, 3-Didehydro-N-Acetyl Neuraminic Acid and their use as Antiviral Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD | The European Patent Office | EP 0 526 543 B1 | Expired |
GG-GP108 | METERING DEVICES AND MAGNETIC CARDS FOR USE WITH SUCH DEVICES | GEC TRAFFIC AUTOMATION LIMITED | United Kingdom | GB2157869 | Expired |
GG-GP107 | MAGNETIC CARD READING DEVICES AND CARDS FOR USE WITH SUCH DEVICES | GEC TRAFFIC AUTOMATION LIMITED | United Kingdom | GB2157868 | Expired |
GG-GP106 | PUMP FOR A DIGGING DEVICE USED FOR DIGGING TRENCHES INTO THE GROUND | SOLETANCHE SOCIÉTÉ ANONYME DITE | The European Patent Office | EP 0 249 555 | Ceased |
GG-GP103 | BENZENEDIMETHANOL SUITABLE FOR MICRONISATION | GLAXO GROUP LIMITED | The European Patent Office | EP 0 639 176 B1 | Expired |
GG-GP102 | CEPHALOSPORIN ANTIBIOTICS | GLAXO GROUP LIMITED | United Kingdom | GB 2152504 B | Ceased |
GG-GP101 | PHARMACEUTICAL COMPOSITION | GLAXO GROUP LIMITED | United Kingdom | GB 2 204 792 B | Expired |
GG-GP98 | DICHLOROANILINE DERIVATIVES | GLAXO GROUP LIMITED | United Kingdom | GB 2187734 B | Ceased |
GG-GP97 | PHARMACEUTICAL COMPOSITIONS | GLAXO CANADA INC | United Kingdom | GB 2 229 094 B | Expired |
GG-GP96 | IMPROVEMENTS RELATING TO SMOKING ARTICLES | BRITISH-AMERICAN TOBACCO COMPANY LIMITED | United Kingdom | GB 2 209 268B | Expired |
GG-GP95 | IMPROVEMENTS RELATING TO SMOKING ARTICLES | BRITISH-AMERICAN TOBACCO COMPANY LIMITED | United Kingdom | GB 2 209 269 B | Expired |
GG-GP94 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED | United Kingdom | GB 2150932 | Ceased |
GG-GP93 | PHARMACEUTICAL FORMULATION | FISONS PLC | United Kingdom | GB 2187953 | Ceased |
GG-GP92 | TRANS-6-[2-(3 OR 4 - CARBOXAMIDO-SUBSTITUTED PYRROL-1-YL)-ALKYL]-4-HYDROXYPYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS | WARNER-LAMBERT COMPANY | The European Patent Office | EP 0247633 | Expired |
GG-GP79 | Therapeutic heterocyclic compounds | ASTRA ZENECA AB | The European Patent Office | EP0486666 | Expired |
GG-GP78 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATION | GLAXO SPA | United Kingdom | GB 2181127 B | Ceased |
GG-GP77 | HIGH TOUGHNESS CERAMICS AND PROCESS FOR THE PREPARATION THEREOF | HITACHI, LTD | The European Patent Office | EP 0 188 129 B1 | Ceased |
GG-GP76 | Water-Dispersible Tablets | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 522 128 B1 | Expired |
GG-GP75 | Water-Dispersible Tablet containing Lamotrigine | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 685 231 B1 | Expired |
GG-GP74 | PHARMACEUTICAL COMPOSITIONS | LABORATOIRES GLAXO S.A | United Kingdom | GB2219940 | Expired |
GG-GP72 | HETEROCYCLIC AMINO COMPOUNDS | GLAXO GROUP LIMITED | The European Patent Office | EP 0 162 593 | Ceased |
GG-GP71 | FUNGICIDAL COMPOSITION BASED ON ALUMINIUM TRIS-(ETHYL PHOSPHONATE) | RHONE-POULENC AGROCHIMIE | United Kingdom | GB 2137498B | Ceased |
GG-GP70 | TELECOMMUNICATIONS DIGITAL SWITCHBLOCK | THE PLESSEY COMPANY | Unknown Jurisdiction | 2125254 | Ceased |
GG-GP69 | PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION | United Kingdom | GB2157686B | Ceased |
GG-GP68 | PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION | United Kingdom | GB2146989B | Ceased |
GG-GP67 | ELECTRONIC DETECTION CIRCUIT | THE PLESSEY COMPANY LIMITED | United Kingdom | GB 2072461B | Ceased |
GG-GP66 | PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION | United Kingdom | GB 2146989B | Expired |
GG-GP65 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP0 349 242 B1 | Expired |
GG-GP64 | MAGNETIC CARD READING DEVICES AND CARDS FOR USE WITH SUCH DEVICES | GEC TRAFFIC AUTOMATION LIMITED | United Kingdom | GB 2157868 | Expired |
GG-GP63 | METERING DEVICES AND MAGNETIC CARDS FOR USE WITH SUCH DEVICES | GEC TRAFFIC AUTOMATION LIMITED | United Kingdom | GB 2157869 | Expired |
GG-GP62 | HETEROCYCLIC AMINO COMPOUNDS | GLAXO GROUP LIMITED | United Kingdom | GB 2157691B | Expired |
GG-GP61 | LACTAM DERIVATIVES | GLAXO GROUP LIMITED | United Kingdom | GB 2209335 B | Expired |
GG-GP60 | AMINOCYCLOPENTANOL ACIDS AND ESTERS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATION | GLAXO GROUP LIMITED | United Kingdom | GB 2097397 | Ceased |
GG-GP59 | IMPROVEMENTS IN OR RELATING TO METHODS AND APPARATUS FOR THE CONTINUOUS FORMATION OF AN EXTRUDED PRODUCT | NATIONAL RESEARCH DEVELOPMENT CORPORATION | United Kingdom | GB 2237237B | Ceased |
GG-GP58 | PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION | Unknown Jurisdiction | GB 2136806B | Ceased |
GG-GP56 | PROCESS FOR THE STABILISATION OF A SOLID PHARMACEUTICAL COMPOSITION COMPRISING CYCLIC AMINO ACIDS | GODECKE AKTIENGESELLSCHAFT | The European Patent Office | EP 0 414 263 B1 | Expired |
GG-GP55 | New oxime derivatives of 7-amino-thiazolylacetamido-cephalosporanic acid, process for preparing them and pharmaceutical compositions incorporating them | ROUSSEL-UCLAF | United Kingdom | GB 1 580 621 | Expired |
GG-GP54 | Crystalline form of the sodium salt of an oxyimino derivative of the 7-aminothiazolylacetamido-cephalosporanic acid, process for its preparation and pharmaceutical compositions containing it | ROUSSEL-UCLAF | The European Patent Office | EP 0 001 024 B1 | Expired |
GG-GP53 | MEDICAMENTS | GLAXO GROUP LIMITED | United Kingdom | GB2235627 B | Revoked |
GG-GP52 | PIPERIDINYLCYCLOPENTANOL HEPTENOIC ACID SALT | GLAXO GROUP LIMITED | United Kingdom | GB2127406 | Ceased |
GG-GP51 | PROCESS AND APPARATUS FOR PRODUCING GLAZED CERAMIC TILES, AND TILES SO OBTAINED | CERAMICA FILIPPO MARAZZI SPA | United Kingdom | GB 2,171,402B | Ceased |
GG-GP50 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY LIMITED | The European Patent Office | EP 0 454 436 B1 | Expired |
GG-GP49 | HETEROCYCLIC DERIVATIVES | GLAXO SPA | United Kingdom | GB2164336B | Expired |
GG-GP48 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLONE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED | The European Patent Office | EP 0 526 529 B1 | Expired |
GG-GP47 | New herbicidal nicotinamide derivatives | RHONE-POULENC AGRICULTURE LIMITED | The European Patent Office | EP 0053011 | Expired |
GG-GP46 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES | BEECHAM GROUP PLC | The European Patent Office | EP 0 306 228 B1 | Expired |
GG-GP45 | LACTAM DERIVATIVES | GLAXO GROUP LIMITED | United Kingdom | GB 2209335 C | Expired |
GG-GP44 | CRYSTALLINE 4-AMINO-1-HYDROXYBUTYLIDENE-1, 1-BISPHOSPHONIC ACID MONOSODIUM TRIHYDRATE, PROCESS THEREFOR AND COMPOSITIONS AND USE THEREOF | MERCK & CO. INC. | The European Patent Office | EP 0 402 152 B1 | Expired |
GG-GP42 | PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION | United Kingdom | GB2136806 | Expired |
GG-GP41 | 3-HYDROXYPRYND-2AND-4-ONES | NATIONAL RESEARCH DEVELOPMENT CORPORATION | United Kingdom | GB2136807 | Expired |
GG-GP40 | PHARMACEUTICAL COMPOSITIONS CONTAINING 1-HYDROXYPYRID-2-ONE DERIVATIVES | NATIONAL RESEARCH DEVELOPMENT CORPORATION | The European Patent Office | EP0138420 | Ceased |
GG-GP39 | IMPROVEMENTS IN OR RELATING TO A STEROID COMPOUND AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | GLAXO GROUP LIMITED | United Kingdom | GB2107715B | Expired |
GG-GP38 | INDIVIDUAL PARKING METER | JON LIE | Unknown Jurisdiction | GB2177836 | Ceased |
GG-GP37 | OPTICAL FSK DEMODULATOR | THE PLESSEY COMPANY PLC | United Kingdom | GB2198904 B | Ceased |
GG-GP35 | PLANE HOLLOW REINFORCED CONCRETE FLOOR WITH TWO-DIMENSIONAL STRUCTURE | BREUNING, Jorgen Illner | The European Patent Office | EP 0 552 201 B1 | Expired |
GG-GP34 | OPTICAL FIBRE STORAGE APPARATUS | GEC PLESSEY TELECOMMUNICATIONS LTD | Unknown Jurisdiction | GB2241221 B | Ceased |
GG-GP33 | TDM DATA TRANSMISSION SYSTEM | GEC PLESSEY TELECOMMUNICATIONS LTD | United Kingdom | GB2218598 B | Ceased |
GG-GP32 | IMPROVEMENTS IN OR RELATING TO ELECTRIC OSCILLATOR CIRCUIT ARRANGEMENTS | GENERAL ELECTRIC COMPANY LIMITED | United Kingdom | GB1603616 | Expired |
GG-GP31 | Digital Data Signalling Systems & Apparatus | GENERAL ELECTRIC COMPANY LIMITED | United Kingdom | GB1489177 | Expired |
GG-GP30 | HOUSING ARRANGEMENTS FOR ELECTRICAL/OR ELECTRONIC EQUIPMENT | THE GENERAL ELECTRIC COMPANY P L C | United Kingdom | GB2196798 B | Expired |
GG-GP29 | POWER SYSTEM FOR TELEPHONY SYSTEMS | GPT LIMITED | United Kingdom | GB2249239 B | Ceased |
GG-GP27 | FIBRE OPTIC CONNECTOR | GEC PLESSEY TELECOMMUNICATIONS LIMITED | United Kingdom | GB2233787 B | Ceased |
GG-GP25 | OXIMES DERIVED FROM ERYTHROMYCIN A, THEIR PREPARATION, THEIR APPLICATION IN PHARMACEUTICALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF | The European Patent Office | EP 0 033 255 B1 | Expired |
GG-GP24 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES | ICI AUSTRALIA LIMITED | The European Patent Office | EP 0 080 301 B1 | Expired |
GG-GP22 | PIPERIDINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | ASTRAZENECA AB | The European Patent Office | EP 1 499 590 B8 | Ceased |
GG-GP21 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (1) | ASTRAZENECA AB | The European Patent Office | EP 1 084 103 B1 | Ceased |
GG-GP20 | METHOD FOR THE PREPARATION OF ARYL ETHERS | PHARAMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 140 788 B1 | Ceased |
GG-GP19 | (S, S)-REBOXETINE FOR TREATING MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 459 751 B1 | Ceased |
GG-GP18 | (S,S)-REBOXETINE FOR TREATING PERIPHERAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 459 748 B1 | Ceased |
GG-GP17 | REBOXETINE FOR TREATING MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 500 396 B1 | Ceased |
GG-GP16 | (S, S)-REBOXETINE FOR TREATING INCONTINENCE | PHARMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 459 749 B1 | Ceased |
GG-GP15 | REBOXETINE FOR TREATING PERIPHERAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC | The European Patent Office | EP 1 493 442 B1 | Ceased |
GG-GP14 | PYRIDAZINO QUINOLINE COMPOUNDS | ASTRAZENECA AB | The European Patent Office | EP 0 724 583 B1 | Ceased |
GG-GP13 | PROCESS FOR PREPARING OXAZOLINES FROM TETRAHYDROFURANS | Agouron Pharmaceuticals INC | The European Patent Office | EP 1 224 177 B1 | Ceased |
GG-GP12 | POLYMORPH OF 5-[4-[2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY]BENZYL]THIAZOLIDINE-2, 4-DIONE MALEIC ACID SALT | SMITHKLINE BEECHAM PLC AND SMITHKLINE BEECHAM (CORK) LIMITED | The European Patent Office | EP 1 173 435 B1 | Ceased |
GG-GP11 | Triazine Compounds as Anxiolytics | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 689 440 B1 | Ceased |
GG-GP10 | USE OF 3,5-DIAMINO-6-(2,3-DICHLOROPHENYL)-1, 2, 4-TRIAZINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT CERTAIN TYPES OF PAIN AND OF OEDEMA | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 626 851 B1 | Ceased |
GG-GP9 | HYPOLIPIDAEMIC BENZOTHIAZEPINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED | The European Patent Office | EP 0 626 952 B1 | Ceased |
GG-GP8 | 1, 5-Benzodiazepine Derivatives and their use in medicine | GLAXO WELLCOME SpA | The European Patent Office | EP 0 558 104 B1 | Ceased |
GG-GP7 | NEW FORMULATION FOR INHILATION HAVING A POURED BULK DENSITY OF FROM 0.28 TO 0.38 G/ML, COMPRISING TERBUTALINE SULPHATE, A PROCESS FOR PREPARING THE FORMULATION AND THE USE THEREOF | ASTRAZENECA AB | The European Patent Office | EP 1 014 955 B1 | Ceased |
GG-GP6 | BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB | The European Patent Office | EP 0850232 B1 | Ceased |
GG-GP5 | MULTILAYER TABLET COMPRISING ROSIGLITAZONE | SMITHKLINE BEECHAM PLC | The European Patent Office | EP 1 128 827 B1 | Ceased |
GG-GP3 | MULTILAYER TABLET COMPRISING ROSIGLITAZONE | SMITHKLINE BEECHAM PLC | The European Patent Office | EP 1 128 827 B1 | Ceased |
GG-GP2 | FORM III CRYSTALLINE [R-(R*,R*)] -2-(4-FLUOROPHENYL)-BETA-DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[PHENYLAMINO) CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN) | WARNER-LAMBERT COMPANY | The European Patent Office | EP 0 848 704 B1 | Ceased |
GG-GP1 | STABILISATION OF PHOSPHORIC ACID ESTERS | HOECHST AKTIENGESELLSCHAFT | United Kingdom | GB2000975 | Ceased |